These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12781431)

  • 1. Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone.
    Jeremic B; Shibamoto Y; Milicic B; Dagovic A; Nikolic N; Aleksandrovic J; Acimovic L; Milisavljevic S
    Lung Cancer; 2003 Jun; 40(3):317-23. PubMed ID: 12781431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
    Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
    Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interfraction interval in patients with stage III non-small-cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy: final results in 536 patients.
    Jeremic B; Milicic B; Dagovic A; Aleksandrovic J; Milisavljevic S
    Am J Clin Oncol; 2004 Dec; 27(6):616-25. PubMed ID: 15577441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
    Jeremić B; Milicić B
    Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage III non-small-cell lung cancer treated with high-dose hyperfractionated radiation therapy and concurrent low-dose daily chemotherapy with or without weekend chemotherapy: retrospective analysis of 301 patients.
    Jeremic B; Milicic B; Dagovic A; Aleksandrovic J; Milisavljevic S
    Am J Clin Oncol; 2004 Aug; 27(4):350-60. PubMed ID: 15289727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trial.
    Fu XL; Jiang GL; Wang LJ; Qian H; Fu S; Yie M; Kong FM; Zhao S; He SQ; Liu TF
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):545-52. PubMed ID: 9336130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer in octogenarians and older: an alternative treatment.
    Bei Y; Murakami N; Nakayama Y; Okuma K; Kashihara T; Raturi VP; Okamoto H; Takahashi K; Inaba K; Igaki H; Itami J
    J Radiat Res; 2020 Jul; 61(4):586-593. PubMed ID: 32383730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
    Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
    Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
    Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of interfraction interval on local tumor control in patients with limited-disease small-cell lung cancer treated with radiochemotherapy.
    Jeremić B; Milićić B
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):426-32. PubMed ID: 17306936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
    Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation therapy of stage I and II non-small cell lung cancer (NSCLC).
    Zierhut D; Bettscheider C; Schubert K; van Kampen M; Wannenmacher M
    Lung Cancer; 2001 Dec; 34 Suppl 3():S39-43. PubMed ID: 11740992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.
    Sibley GS; Jamieson TA; Marks LB; Anscher MS; Prosnitz LR
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):149-54. PubMed ID: 9422571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.
    Zheng X; Sun Y; Ye K; Fan C; Wang X; Yang Y; Jiao R; Ge H
    Thorac Cancer; 2021 Mar; 12(6):899-905. PubMed ID: 33529496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results.
    King SC; Acker JC; Kussin PS; Marks LB; Weeks KJ; Leopold KA
    Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):593-9. PubMed ID: 8948343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.
    Jeremic B; Shibamoto Y; Acimovic L; Milisavljevic S
    J Clin Oncol; 1996 Apr; 14(4):1065-70. PubMed ID: 8648358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.
    Feng W; Zhang Q; Fu XL; Cai XW; Zhu ZF; Yang HJ; Xiang JQ; Zhang YW; Chen HQ
    BMC Cancer; 2015 May; 15():348. PubMed ID: 25934006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
    Werner-Wasik M; Scott C; Graham ML; Smith C; Byhardt RW; Roach M; Andras EJ
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):327-31. PubMed ID: 10760427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter.
    Pradier O; Lederer K; Hille A; Weiss E; Christiansen H; Schmidberger H; Hess CF
    J Cancer Res Clin Oncol; 2005 Apr; 131(4):261-9. PubMed ID: 15616830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04.
    Komaki R; Seiferheld W; Ettinger D; Lee JS; Movsas B; Sause W
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):548-57. PubMed ID: 12062596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.